Please login to the form below

Not currently logged in
Email:
Password:

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

in previously-untreated patients with extensive-stage SCLC, said to be the most aggressive for of lung cancer. ... SCLC is less common than non-small cell lung cancer (NSCLC) but tends to be more aggressive, growing more quickly and spreading to other

Latest news

More from news
Approximately 3 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  .

  • Deal Watch April 2016 Deal Watch April 2016

    Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.

  • Deal Watch November 2015 Deal Watch November 2015

    July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics